MCID: LNG017
MIFTS: 53

Lung Giant Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Giant Cell Carcinoma

MalaCards integrated aliases for Lung Giant Cell Carcinoma:

Name: Lung Giant Cell Carcinoma 12 15 17
Carcinoma, Giant Cell 43 71
Giant Cell Carcinoma of Lung 71
Giant Cell Lung Carcinoma 12
Giant Cell Carcinoma 12
Carcinoma Giant Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:5583
MeSH 43 D018286
NCIt 49 C3779 C4452
SNOMED-CT 67 254631008 42596004
UMLS 71 C0206703 C0345960

Summaries for Lung Giant Cell Carcinoma

Disease Ontology : 12 A lung carcinoma that is located in large undifferentiated cells.

MalaCards based summary : Lung Giant Cell Carcinoma, also known as carcinoma, giant cell, is related to spindle cell carcinoma and carcinosarcoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Lung Giant Cell Carcinoma is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include large undifferentiated cells, lung and pancreas, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Related Diseases for Lung Giant Cell Carcinoma

Diseases related to Lung Giant Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 337)
# Related Disease Score Top Affiliating Genes
1 spindle cell carcinoma 30.4 VIM KRT18 CDH1
2 carcinosarcoma 29.7 VIM CDKN2A CDH1
3 bronchitis 29.6 VEGFA MMP9 CXCL8
4 benign giant cell tumor 29.6 VIM SERPINA3 MMP9
5 castleman disease 29.5 VEGFA IL6R CXCL8
6 hydronephrosis 29.5 VEGFA TIMP1 MMP9 CXCL8
7 endometrial adenocarcinoma 29.5 VIM VEGFA CDKN2A CDH1
8 mucoepidermoid carcinoma 29.5 SERPINA3 CDKN2A CDH1
9 transitional cell carcinoma 29.4 NME1 MMP9 KRT18 CDKN2A CDH1
10 angiosarcoma 29.4 VIM VEGFA MYC
11 spindle cell sarcoma 29.3 VIM VEGFA SERPINA3
12 liposarcoma 29.3 VIM MYC CDKN2A
13 pulmonary disease, chronic obstructive 29.3 TIMP1 SERPINA3 MMP9 CXCL8
14 rhabdomyosarcoma 29.0 VIM VEGFA MYC CDKN2A
15 melanoma, uveal 28.7 VEGFA NME1 MYC MMP2 CDKN2A
16 adenocarcinoma 28.6 VEGFA TIMP1 MYC MMP9 MMP2 CDKN2A
17 ovarian serous cystadenocarcinoma 28.5 VEGFA SERPINA3 MYC CDKN2A CDH1
18 sarcoma 28.4 VIM VEGFA SERPINA3 MYC CXCL8
19 squamous cell carcinoma 28.0 VEGFA NME1 MYC MMP9 MMP2 CDKN2A
20 pancreatic cancer 27.9 VEGFA SERPINA3 MYC MMP9 MMP2 CXCL8
21 pancreatic adenocarcinoma 27.8 VEGFA TIMP1 MYC MMP9 MMP2 CXCL8
22 lung cancer susceptibility 3 27.5 VEGFA SERPINA3 MYC MMP9 MMP2 KRT18
23 endometrial cancer 27.4 VEGFA TIMP1 SERPINA3 NME1 MYC MMP9
24 lung cancer 26.8 VEGFA TIMP1 SERPINA3 NME1 MYC MMP9
25 hepatocellular carcinoma 26.0 VEGFA TIMP1 SERPINA3 NME1 MYC MMP9
26 breast cancer 25.1 VIM VEGFA TIMP1 SERPINA3 NME1 MYC
27 ovarian cancer 24.6 VIM VEGFA TIMP1 SERPINA3 NME1 MYC
28 autoimmune inner ear disease 10.4 TIMP1 MMP9
29 vulvar intraepithelial neoplasia 10.4 CDKN2A CDH1
30 esophagus verrucous carcinoma 10.4 CDKN2A CDH1
31 extracranial arteriovenous malformation 10.4 MMP9 MMP2
32 focal myositis 10.4 MMP9 MMP2
33 fungal keratitis 10.4 TIMP1 MMP9
34 lentigo maligna melanoma 10.4 MMP9 MMP2
35 spastic entropion 10.3 MMP9 MMP2
36 nasal cavity squamous cell carcinoma 10.3 MMP9 MMP2
37 light chain deposition disease 10.3 MMP9 MMP2
38 stomach disease 10.3 TIMP1 CXCL8 CDH1
39 cardiac rupture 10.3 MMP9 CXCL8
40 odontoma 10.3 VIM KRT18
41 villonodular synovitis 10.3 VIM MMP9
42 cryptogenic organizing pneumonia 10.3 TIMP1 MMP9 CXCL8
43 gingival overgrowth 10.3 TIMP1 MMP2 CXCL8
44 lymphoma, large-cell, immunoblastic 10.3 TIMP1 MYC
45 endometrial mucinous adenocarcinoma 10.2 VIM CDKN2A
46 ameloblastic carcinoma 10.2 VIM CDKN2A
47 acute transverse myelitis 10.2 MMP9 MMP2 CXCL8
48 transverse myelitis 10.2 MMP9 MMP2 CXCL8
49 appendicitis 10.2 TIMP1 MMP9 CXCL8
50 bronchiolitis obliterans 10.2 TIMP1 MMP9 CXCL8

Graphical network of the top 20 diseases related to Lung Giant Cell Carcinoma:



Diseases related to Lung Giant Cell Carcinoma

Symptoms & Phenotypes for Lung Giant Cell Carcinoma

UMLS symptoms related to Lung Giant Cell Carcinoma:


fever, dyspnea, hemoptysis, coughing

GenomeRNAi Phenotypes related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 CDH1 CXCL8 IL6R KRT18 MMP2 MYC

MGI Mouse Phenotypes related to Lung Giant Cell Carcinoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.26 CDH1 CDKN2A GJA1 IL6R MMP2 MMP9
2 growth/size/body region MP:0005378 10.25 CDH1 CDKN2A GJA1 IL6R KRT18 MMP2
3 immune system MP:0005387 10.2 CDH1 CDKN2A GJA1 IL6R MMP2 MMP9
4 cardiovascular system MP:0005385 10.19 CDH1 CDKN2A GJA1 MMP2 MMP9 MYC
5 hematopoietic system MP:0005397 10.19 CDKN2A GJA1 IL6R MMP2 MMP9 MTSS1
6 mortality/aging MP:0010768 10.18 CDH1 CDKN2A GJA1 IL6R KRT18 MMP2
7 endocrine/exocrine gland MP:0005379 10.13 CDH1 CDKN2A GJA1 IL6R MYC NME1
8 integument MP:0010771 10.03 CDH1 CDKN2A GJA1 MMP9 MYC NME1
9 neoplasm MP:0002006 9.96 CDH1 CDKN2A IL6R MMP2 MMP9 MTSS1
10 liver/biliary system MP:0005370 9.95 CDKN2A IL6R KRT18 MTSS1 MYC NME1
11 muscle MP:0005369 9.87 CDKN2A GJA1 MMP2 MMP9 MYC VEGFA
12 reproductive system MP:0005389 9.76 CDH1 CDKN2A GJA1 MMP9 MYC TIMP1
13 respiratory system MP:0005388 9.5 CDKN2A GJA1 MMP2 MMP9 TIMP1 VEGFA
14 skeleton MP:0005390 9.23 CDKN2A GJA1 MMP2 MMP9 MTSS1 MYC

Drugs & Therapeutics for Lung Giant Cell Carcinoma

Drugs for Lung Giant Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
3
Ipilimumab Approved Phase 2 477202-00-9
4
nivolumab Approved Phase 2 946414-94-4
5 Protein Kinase Inhibitors Phase 2
6
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
7 Albumin-Bound Paclitaxel Phase 2
8 Tubulin Modulators Phase 2
9 Antimitotic Agents Phase 2
10 Immunoglobulins Phase 2
11 Antibodies Phase 2
12 Antibodies, Monoclonal Phase 2
13 Antineoplastic Agents, Immunological Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Completed NCT00563784 Phase 2 Erlotinib;Carboplatin;Paclitaxel
2 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
3 Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma Terminated NCT00568906

Search NIH Clinical Center for Lung Giant Cell Carcinoma

Cochrane evidence based reviews: carcinoma, giant cell

Genetic Tests for Lung Giant Cell Carcinoma

Anatomical Context for Lung Giant Cell Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Giant Cell Carcinoma:

19
Large Undifferentiated Cells

MalaCards organs/tissues related to Lung Giant Cell Carcinoma:

40
Lung, Pancreas, Thyroid, Skeletal Muscle, Liver, Breast, Myeloid

Publications for Lung Giant Cell Carcinoma

Articles related to Lung Giant Cell Carcinoma:

(show top 50) (show all 62)
# Title Authors PMID Year
1
[Expression of connexin 43 in lung cancer and its correlation with E-cadherin]. 54 61
16834907 2006
2
Effect of interleukin-6 on the growth of human lung cancer cell line. 61 54
10374431 1998
3
Extremely Aggressive Behavior of a Completely Resected Case of Gallbladder Undifferentiated Carcinoma, Giant Cell Type: a Rare Case with Breast, Neck Nodes, and Subcutaneous Scalp Nodules Metastasis. 61
31155696 2020
4
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. 61
31824199 2019
5
[Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma]. 61
30591097 2018
6
A Rare Case of Sarcomatoid Carcinoma of the Lung with Spine Metastasis, Including a Literature Review. 61
28684728 2017
7
Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. 61
28445978 2017
8
Missing in metastasis B, regulated by DNMT1, functions as a putative cancer suppressor in human lung giant-cell carcinoma. 61
28159994 2017
9
[Pulmonary sarcomatoid carcinoma]. 61
26778815 2016
10
A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy. 61
27111877 2016
11
[Sarcomatoid carcinoma of the lung: retrospective study of 28 cases]. 61
24703022 2014
12
A case report of anaplastic carcinoma of the pancreas with remarkable intraductal tumor growth into the main pancreatic duct. 61
24574758 2014
13
Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. 61
24088577 2013
14
[Pulmonary sarcomatoid carcinoma]. 61
22889810 2012
15
Sarcomatoid neoplasms of the lung and pleura. 61
21043818 2010
16
Review article: pulmonary sarcomatoid carcinomas: a practical overview. 61
19124452 2010
17
[PAR-1 regulation of intracellular Ca²(+) mobilization in pulmonary giant cell carcinoma cell line PLA801D/PLA801C]. 61
20388375 2010
18
[A case of carcinosarcoma in the liver]. 61
19835222 2009
19
Undifferentiated giant cell type carcinoma of the gallbladder with sarcomatoid dedifferentiation: a case report and review of the literature. 61
19830109 2009
20
[Two cases of anaplastic carcinoma of the pancreas in terms of the diversity of carcinoma cells (epithelial-mesenchymal transition; EMT)]. 61
18987452 2008
21
[Expression and clinical significance of RhoC and RhoGDIa in non-small cell lung cancer.]. 61
20731941 2008
22
[Functional aspects of protease-activated receptor 1 in promoting metastasis of lung cancer]. 61
17706138 2007
23
A case of anaplastic ductal carcinoma of the pancreas with production of granulocyte-colony stimulating factor. 61
17153462 2006
24
Establishment and characterization of a human thyroid carcinoma cell line (HOTHC) producing colony stimulating factor. 61
17022149 2005
25
[A case of anaplastic ductal carcinoma (giant cell carcinoma of osteoclastoid type) with portal vein and main pancreatic ductal invasion]. 61
15981633 2005
26
Effective asymmetry in gap junctional intercellular communication between populations of human normal lung fibroblasts and lung carcinoma cells. 54
14656943 2004
27
[Identification of novel metastasis associated genes MAG-1 and MAG-2]. 61
21310131 2003
28
[Study on differentially expressed molecules influencing the metastatic potential between highly and poorly metastatic human lung giant cell carcinoma]. 61
14690554 2003
29
[Function of IL-18 in promoting metastasis of lung cancer]. 61
12921563 2003
30
Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features. 61
14533941 2003
31
Experimental study on mechanism and rarity of metastases in skeletal muscle. 61
12609079 2002
32
cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. 61
11410166 2001
33
[Regulatory effect of antisense VEGF121 cDNA transfection on angiogenesis and metastasis of human lung giant cell carcinoma]. 61
11236636 2000
34
An assessment of the aggressive potential of radiolucencies related to the mandibular molar teeth. 61
10767189 2000
35
Pleomorphic giant cell carcinoma of the esophagus with coexpression of cytokeratin and vimentin and neuroendocrine differentiation. 54
10629146 2000
36
[Pathological and immunohistochemical analysis of giant cells of pancreas]. 54
9391326 1997
37
[Differential expression and response of growth factors in metastatic variants of human pulmonary giant cell carcinoma cell line]. 54
10072879 1997
38
[Influence of transfection of sense- and antisense-TGF beta 1 gene on human pulmonary giant cell carcinoma cell proliferation]. 54
10743067 1997
39
[Growth regulatory mechanisms of recombinant human interleukin-6 on human lung carcinoma cell lines]. 61
9596958 1997
40
[Interleukin-6 behaves as an autocrine growth stimulator for a human lung giant cell carcinoma cell line]. 61
10072840 1997
41
[Mutation of P53 gene in a highly metastatic human lung cancer cell line]. 61
7587895 1995
42
[Isolation and characterization of human lung cancer cell subline with different metastatic potential]. 61
7656376 1995
43
[Effects of metalloproteinases-1 (TIMP-1) cDNA transfection on biological behaviors of PG cells]. 54
7987710 1994
44
[Studies on the reduction of malignant phenotypes in a highly metastatic human lung carcinoma--correlated changes of intercellular communication, cytoskeletons, oncogenes and antioncogene]. 61
7924870 1994
45
Selective effect of O-alkyl lysophospholipids on the growth of a human lung giant cell carcinoma cell line. 61
8017834 1994
46
Characterization of a 64-kd protein phosphorylated during chemotactic activation with IL-8 and fMLP of human polymorphonuclear leukocytes. II. Purification and amino acid analysis of phosphorylated 64-kd protein. 61
8336074 1993
47
Characterization of a 64-kd protein phosphorylated during chemotactic activation with IL-8 and fMLP of human polymorphonuclear leukocytes. I. Phosphorylation of a 64-kd protein and other proteins. 61
8393062 1993
48
Isolation and amino acid sequence of a chemotactic protein, LECT/interleukin 8, from a human myeloid leukemia cell line, ML-1. 61
8344717 1993
49
Unusual forms of carcinoma of the urinary bladder. 61
1842384 1991
50
[Orthotopic xenotransplantation of human lung giant cell carcinoma and study on its invasion and metastasis]. 61
1782686 1991

Variations for Lung Giant Cell Carcinoma

Cosmic variations for Lung Giant Cell Carcinoma:

9 (show top 50) (show all 1546)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 15
2 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 15
3 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 15
4 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 15
5 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 15
6 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
7 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
8 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 15
9 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 15
10 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 15
11 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 15
12 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 15
13 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 15
14 COSM127070824 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 8:102305221-102305221 15
15 COSM127059821 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 8:102326590-102326590 15
16 COSM85195038 U2AF1 lung,NS,carcinoma,undifferentiated carcinoma c.319G>C p.D107H 21:43095467-43095467 15
17 COSM130300868 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 19:10350838-10350838 15
18 COSM131090496 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.1922C>T p.S641L 14:81143980-81143980 15
19 COSM131094722 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.412C>T p.L138F 14:81091088-81091088 15
20 COSM131094002 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.937A>C p.K313Q 14:81142995-81142995 15
21 COSM87049256 TSC2 lung,NS,carcinoma,undifferentiated carcinoma c.1840G>T p.A614S 16:2071510-2071510 15
22 COSM85721789 TSC1 lung,NS,carcinoma,undifferentiated carcinoma c.694G>T p.E232* 9:132921406-132921406 15
23 COSM90140992 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1193C>T p.P398L 16:2173978-2173978 15
24 COSM90145840 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1287C>G p.Y429* 16:2174274-2174274 15
25 COSM87090089 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 1:211356392-211356392 15
26 COSM87898991 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 17:7675077-7675077 15
27 COSM87901497 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.461G>T p.G154V 17:7675151-7675151 15
28 COSM87935416 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.499C>T p.Q167* 17:7675113-7675113 15
29 COSM87904420 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.514G>T p.V172F 17:7675098-7675098 15
30 COSM87898444 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.536A>G p.H179R 17:7675076-7675076 15
31 COSM87906107 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.473G>T p.R158L 17:7675139-7675139 15
32 COSM87909792 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.919+1G>T p.? 17:7673700-7673700 15
33 COSM87940740 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.811G>T p.E271* 17:7673809-7673809 15
34 COSM87899785 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.991C>T p.Q331* 17:7673537-7673537 15
35 COSM87902162 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.783-1G>T p.? 17:7673838-7673838 15
36 COSM87915599 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.842A>G p.D281G 17:7673778-7673778 15
37 COSM87897914 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.527G>T p.C176F 17:7675085-7675085 15
38 COSM87899377 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.375+1G>A p.? 17:7675993-7675993 15
39 COSM87900565 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.1024C>T p.R342* 17:7670685-7670685 15
40 COSM87918616 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.993+1G>A p.? 17:7673534-7673534 15
41 COSM87897711 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.818G>A p.R273H 17:7673802-7673802 15
42 COSM87900157 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.818G>T p.R273L 17:7673802-7673802 15
43 COSM87942817 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.376-1G>T p.? 17:7675237-7675237 15
44 COSM87903076 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.796G>T p.G266* 17:7673824-7673824 15
45 COSM87898836 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.560-1G>A p.? 17:7674972-7674972 15
46 COSM87898881 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 17:7674953-7674953 15
47 COSM150205149 TLR4 lung,NS,carcinoma,undifferentiated carcinoma c.337C>A p.P113T 9:117712465-117712465 15
48 COSM85378871 TLR2 lung,NS,carcinoma,undifferentiated carcinoma c.1169A>G p.Q390R 4:153704076-153704076 15
49 COSM90180942 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.5624C>T p.S1875L 9:35705660-35705660 15
50 COSM90180404 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.1087C>T p.P363S 9:35721665-35721665 15

Expression for Lung Giant Cell Carcinoma

Search GEO for disease gene expression data for Lung Giant Cell Carcinoma.

Pathways for Lung Giant Cell Carcinoma

Pathways related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VIM VEGFA TIMP1 SERPINA3 MYC MMP9
2
Show member pathways
13.7 VIM VEGFA TIMP1 MYC KRT18 IL6R
3
Show member pathways
13.22 VIM VEGFA TIMP1 MYC MMP9 MMP2
4
Show member pathways
12.83 VEGFA MYC IL6R CXCL8 CDKN2A
5
Show member pathways
12.76 VEGFA MYC MMP9 CDKN2A CDH1
6 12.48 VEGFA MYC MMP9 MMP2 IL6R CXCL8
7 12.44 VIM VEGFA MYC MMP9 CDKN2A
8 12.42 VIM MTSS1 KRT18 GJA1 CDH1
9 12.2 VEGFA MYC MMP9 MMP2
10 12.09 VEGFA IL6R GJA1 CXCL8
11 11.99 VIM VEGFA MYC GJA1
12 11.95 MMP9 MMP2 GJA1 CDH1
13 11.95 VEGFA MYC MMP9 MMP2 IL6R CDH1
14 11.88 VIM MYC MMP9 GJA1 CXCL8
15 11.86 VEGFA TIMP1 IL6R
16 11.85 IL6R CXCL8 CDKN2A
17 11.82 VEGFA MMP2 CXCL8
18
Show member pathways
11.81 TIMP1 MMP9 MMP2
19 11.75 TIMP1 MMP9 MMP2
20
Show member pathways
11.73 TIMP1 MYC IL6R
21 11.7 NME1 MYC MMP9
22 11.62 MYC MMP9 MMP2 CXCL8 CDH1
23
Show member pathways
11.6 VEGFA MMP9 MMP2 CXCL8
24 11.59 MMP9 MMP2 CXCL8
25 11.58 TIMP1 MMP9 MMP2 CXCL8
26 11.54 TIMP1 MMP9 MMP2 CXCL8
27
Show member pathways
11.52 MYC MMP9 MMP2
28 11.44 VEGFA MYC IL6R CXCL8
29 11.36 VEGFA MYC MMP9 MMP2 CXCL8 CDKN2A
30 11.28 VIM VEGFA TIMP1 MYC MMP9 MMP2
31 11.2 MMP9 MMP2 GJA1 CXCL8
32 10.98 VEGFA TIMP1 SERPINA3
33 10.91 VIM CDH1

GO Terms for Lung Giant Cell Carcinoma

Cellular components related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 VEGFA TIMP1 SERPINA3 MMP9 MMP2 IL6R
2 extracellular matrix GO:0031012 9.26 VEGFA TIMP1 MMP9 MMP2
3 platelet alpha granule lumen GO:0031093 8.8 VEGFA TIMP1 SERPINA3

Biological processes related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.83 VEGFA TIMP1 MYC MMP9 KRT18
2 positive regulation of gene expression GO:0010628 9.72 VIM VEGFA MYC GJA1 CDKN2A
3 platelet degranulation GO:0002576 9.69 VEGFA TIMP1 SERPINA3
4 extracellular matrix disassembly GO:0022617 9.58 TIMP1 MMP9 MMP2
5 positive regulation of epithelial cell proliferation GO:0050679 9.54 VEGFA NME1 MYC
6 response to amyloid-beta GO:1904645 9.49 MMP9 MMP2
7 induction of positive chemotaxis GO:0050930 9.48 VEGFA CXCL8
8 negative regulation of trophoblast cell migration GO:1901164 9.46 TIMP1 GJA1
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.43 MYC MMP2 IL6R
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.33 MMP9 MMP2 GJA1
11 cytokine-mediated signaling pathway GO:0019221 9.23 VIM VEGFA TIMP1 MYC MMP9 MMP2
12 positive regulation of DNA binding GO:0043388 9.13 NME1 MYC MMP9

Molecular functions related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.5 VIM VEGFA TIMP1 SERPINA3 NME1 MYC

Sources for Lung Giant Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....